MapLight Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Christopher A. Kroeger
- Full Time Employees
- 109
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 800 Chesapeake Drive Redwood City CA United States of America 94063
- IPO Date
- Oct 24, 2025
- CIK
- 0001770069
- Website
- maplightrx.com
- Similar Companies
- Business
- MapLight Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the discovery, development, and delivery of circuit-specific therapeutics for central nervous system (CNS) disorders. The company focuses on developing innovative treatments for brain disorders including schizophrenia, Alzheimer’s disease psychosis, autism spectrum disorder, and Parkinson’s disease. Its core products and pipeline candidates include novel muscarinic receptor agonists such as ML-007C-MA, which is an oral M1/M4 muscarinic receptor modulator currently in Phase 2 clinical trials for schizophrenia and Alzheimer’s disease psychosis. The company’s technology platform leverages proprietary innovations including optogenetics, STARmap spatial transcriptomics, and neural circuit pharmacology to identify and target specific brain circuits implicated in complex neuropsychiatric and neurological diseases. Founded in 2018 and headquartered in the San Francisco Bay Area, MapLight operates primarily in the United States with collaborations across leading academic research institutions. Recently, MapLight completed a significant $372.5 million Series D financing round in mid-2025 led by Forbion and Goldman Sachs, with participation from prominent investors including Sanofi, T. Rowe Price, and Novo Holdings, to advance its CNS therapeutic pipeline. The company also initiated Phase 2 clinical studies for its novel ML-007C-MA compound targeting schizophrenia and Alzheimer’s disease psychosis, positioning it competitively in the CNS market alongside peers such as Bristol Myers Squibb. This financing and clinical advancement reflect strategic growth and a commitment to expanding its product portfolio in neuroscience therapeutics. MapLight’s differentiated approach aims to improve treatment efficacy and tolerability for patients with brain disorders by precisely modulating dysfunctional neural circuits, addressing a critical unmet need in psychiatry and neurology. MapLight’s product offerings extend to multiple clinical candidates in various stages of development, with a focus on therapies that treat symptoms of autism spectrum disorder, Parkinson’s disease, hyperactivity, and impulsivity. Its pipeline includes ML-004, ML-021, and ML-009 among others, targeted for treatment across a broad spectrum of brain disorders. The company also has strategic partnerships and investor backing from leading life sciences and pharmaceutical entities, supporting its rapid development and clinical trial progress. This comprehensive focus on CNS disorders, combined with recent capital infusion and clinical progress, situates MapLight Therapeutics as a notable player in innovative neuropharmaceuticals, advancing therapies that aim to redefine the standard of care for brain disorders.
MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
MapLight Therapeutics to Participate in Upcoming Investor Conferences
This MapLight Insider Sold 69,000 Shares for $2.1 Million at the End of April
MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results
MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results
MapLight's Psychosis Drug Could Deliver Billion-Dollar Upside, Says Analyst
Analysts Set Maplight Therapeutics, Inc. (NASDAQ:MPLT) Target Price at $31.80
MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
MapLight Therapeutics to Participate in Upcoming Investor Conferences
Maplight Therapeutics (NASDAQ:MPLT) Shares Gap Up After Insider Buying Activity
Maplight Therapeutics (NASDAQ:MPLT) Shares Gap Down – Time to Sell?
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Average Recommendation of “Buy” from Brokerages
MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026
MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer's Disease Psychosis
SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies
MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress
Insiders Scoop Up Shares of This Biotech IPO, Energy Giant, and More
MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
MapLight Therapeutics valued at $787 million as shares jump in Nasdaq debut
MapLight Therapeutics Announces Pricing of Initial Public Offering